Document Detail

Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations.
MedLine Citation:
PMID:  16718762     Owner:  NLM     Status:  MEDLINE    
AIM: To evaluate the bioequivalence of ranitidine and bismuth derived from two compound preparations.
METHODS: The bioavailability was measured in 20 healthy male Chinese volunteers following a single oral dose (equivalent to 200 mg of ranitidine and 220 mg of bismuth) of the test or reference products in the fasting state. Then blood samples were collected for 24 h. Plasma concentrations of ranitidine and bismuth were analyzed by high-performance liquid chromatography and inductively coupled plasma-mass spectrometry (ICP-MS), respectively. The non-compartmental method was used for pharmacokinetic analysis. Log-transformed C(max), AUC( (0-t) ) and AUC( (0-infinity) ) were tested for bioequivalence using ANOVA and Schuirmann two-one sided t-test. T(max) was analyzed by Wilcoxon's test.
RESULTS: Various pharmacokinetic parameters of ranitidine derived from the two compound preparations, including C(max), AUC( (0-t)), AUC( (0-infinity)), T(max) and T((1/2)), were nearly consistent with previous observations. These parameters derived from test and reference drug were as follows: C(max) (0.67 +/- 0.21 vs 0.68 +/-0.22 mg/L), AUC( (0-t) ) (3.1 +/- 0.6 vs 3.0 +/- 0.7 mg/L per hour), AUC( (0-infinity) ) (3.3 +/- 0.6 vs 3.2 +/- 0.8 mg/L per hour), T(max) (2.3 +/- 0.9 vs 2.1 +/- 0.9 h) and T((1/2)) (2.8 +/- 0.3 vs 3.1 +/- 0.4 h). In addition, double-peak absorption profiles of ranitidine were found in some Chinese volunteers. For bismuth, those parameters derived from test and reference drug were as follows: C(max) (11.80 +/- 7.36 vs 11.40 +/- 6.55 microg/L), AUC( (0-t) ) (46.65 +/- 16.97 vs 47.03 +/- 21.49 microg/L per hour), T(max) (0.50 +/- 0.20 vs 0.50 +/- 0.20 h) and T((1/2)) (10.2 +/- 2.3 vs 13.0 +/- 6.9 h). Ninety percent of confidence intervals for the test/reference ratio of C(max), AUC( (0-t) ) and AUC( (0-infinity) ) derived from both ranitidine and bismuth were found within the bioequivalence acceptable range of 80%-125%. No significant difference was found in T(max) derived from both ranitidine and bismuth.
CONCLUSION: The two compound preparations are bioequivalent and may be prescribed interchangeably.
Quan Zhou; Zou-Rong Ruan; Hong Yuan; Bo Jiang; Dong-Hang Xu
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  World journal of gastroenterology : WJG     Volume:  12     ISSN:  1007-9327     ISO Abbreviation:  World J. Gastroenterol.     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-05-23     Completed Date:  2006-07-03     Revised Date:  2014-09-09    
Medline Journal Info:
Nlm Unique ID:  100883448     Medline TA:  World J Gastroenterol     Country:  China    
Other Details:
Languages:  eng     Pagination:  2742-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Antacids / pharmacokinetics*
Biological Availability
Bismuth / pharmacokinetics*
Chromatography, High Pressure Liquid
Cross-Over Studies
Histamine H2 Antagonists / blood,  pharmacokinetics*
Ranitidine / blood,  pharmacokinetics*
Reproducibility of Results
Spectrophotometry, Atomic
Therapeutic Equivalency
Time Factors
Reg. No./Substance:
0/Antacids; 0/Histamine H2 Antagonists; 884KT10YB7/Ranitidine; U015TT5I8H/Bismuth

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Splenic vasculopathy in portal hypertension patients.
Next Document:  Modulatory effects of Azadirachta indica on benzo(a)pyrene-induced forestomach tumorigenesis in mice...